Carlos Cervera, MD, PhD

Assistant Professor, Department of Medicine, University of Alberta
Medical Director, Transplant Infectious Diseases

Carlos Cervera received his MD from Autonomous University of Barcelona, Spain, in 1994. He completed residency in Hospital Vall d’Hebron receiving Spanish Board Certification in 2001. After his residency, he joined Hospital Clinic of Barcelona in 2003. He received his PhD for his work on innate immune receptors and post-transplant infections in 2010 from the Department of Medicine, University of Barcelona. Since 2003, Dr. Cervera has been working as infectious diseases specialist with a major focus in transplant infectious disease. In February 2015, he joined the Division of Infectious Diseases, Department of Medicine, at the University of Alberta (Canada).

Dr Cervera’s main research interests include infections in immunosuppressed patients and patients with solid organ transplantation. His doctoral thesis focused on the study of genetic polymorphisms in innate immune receptors and the risk of infections in solid organ transplant recipients. In the field of immunosuppression, he has acquired wide experience with infections related to the use of lymphocyte-depletion drugs, calcineurin inhibitors and mTOR inhibitors, and other immunosuppressants. Other areas of interest include fungal infections, microbiota and viral infections. He is member in good standing of the European Society of Clinical Microbiology and Infectious Diseases, American Society of Transplantation, Canadian Society of Transplantation and Infectious Diseases Society of America. He has authored more than 180 original articles in indexed journals and over 25 book chapters.

Carlos Cervera has been reviewer for numerous Journals that include Clinical Infectious Diseases, Journal of Infectious Diseases, Journal of Heart and Lung Transplantation, American Journal of Transplantation, Transplantation, Liver Transplantation, Transplant Infectious Disease, and others. He is the Medical Director of Transplant Infectious Diseases at the University of Alberta.

Professor Andrew Davies, BSc (Hons), BM (Hons), FRCP, PhD

Professor of Haematological Oncology
Consultant in Medical Oncology

Andrew Davies is a Professor in Haematological Oncology and Consultant Medical Oncologist in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton, United Kingdom.  He was awarded honours in medicine, and also gained a first-class Bachelor of Science degree in Molecular Biology from the University of Southampton. He went on to train in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Professor Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena.  He has extensive experience in early phase trials, including leading several first in man lymphoma studies. He is the former Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Research Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.

Dr. Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and has completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is a professor of medicine at Harvard Medical School and is the director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje’s primary focus is in multiple myeloma and related research. Her laboratory focuses on bone biology and the development of novel therapeutics for multiple myeloma, as well as identifying and validating novel targets and translating them into clinical trials.

Dr. Raje is a member of the American Medical Association, America Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research. Her hope is to continue pursing laboratory and clinical research in the area of multiple myeloma with the goal of translating her efforts to the improvement of patients’ lives.

Dr. Kerry Savage, BSc, MD, MSc

Medical Oncologist at the BC Cancer Agency,
Assistant Professor at the University of British Columbia

Dr Kerry Savage is an Associate Professor with the University of British Columbia and she is a Medical Oncologist and Clinical Scientist at the BC Cancer Agency with the lymphoma tumour group, since 2003. She obtained her medical degree at the University of British Columbia in 1996 and received a Masters of Science in Epidemiology at the Harvard School of Public Health in 2004. Prior to working at British Columbia Cancer Agency, she spent two years at the Dana Farber Cancer Institute in Boston to complete a Lymphoma Research Fellowship under the supervision of Dr. Shipp.
Dr Savage’s research interests include all of the lymphoid cancers with particular interest and the training of new clinical fellows.

Professor H. Miles Prince, AM, MBBS (Hons), MD, FRACP, FRCPA, AFRCMA, MACD, FAHMS

Professor, University of Melbourne
Professor, Monash University
Professor/Director of Molecular Oncology and Cancer Immunology, Epworth Healthcare
Director, Centre for Blood Cell Therapies, Peter MacCallum Cancer Centre

Professor Miles Prince is a specialist haematologist who manages all types of blood-related conditions which include anaemia, bleeding and blood clotting disorders, as well as cancers of the blood. He is a full professor at both The University of Melbourne and Monash University.
Professor Prince is involved in major research programs involving stem cell research and the mechanism of the immune systems control of blood and cancer growth. He is also involved in many clinical trials related to this research. He holds major Australian, American and European research grants and has published over 300 journal articles. Professor Prince is a member of Australian, American and European Societies of Haematology and Oncology, and is on the boards of International SOciety of cutaneous lymphoma, InternationalWaldenstrom’s macroglobulinemia Foundation and chairman of the Medical Scientific Advisory Group of Myeloma Australia. Professor Prince has recently been appointed Director of Molecular Oncology and Cancer Immunology at the Epworth Hospital